【摘要】 [目的]探讨P-170在急性白血病中的表达及其与该疾病预后的关系。[方法]选取191例急性白血病患者,其中初发患者127例[急性非淋巴细胞白血病(AML)组94例,急性淋巴细胞白血病(ALL)组33例],复发患者64例(AML组45例,ALL组19例)。流式细胞仪测定上述病人骨髓细胞表面P-170的表达,并计算各组病人P-170的表达率。此外,对所有初发患者进行正规化疗,比较P-170阴性患者与阳性患者治疗的完全缓解率。[结果]初发AML组P-170表达率为(18.34±12.19)%,P-170阳性患者率为12.7%(12/94);初发ALL组P-170表达率为(16.25±11.47)%,P-170阳性患者率为15.1%(5/33)。与初发组病人相比较,复发AML和ALL组P-170表达率和P-170阳性患者率均明显高于相应的初发组[复发AML组(35.29±16.82)%,68.8%(31/45),P<0.01;复发ALL组(38.24±12.17)%,68.4%(13/19),P<0.01]。无论初发AML或ALL,正规化疗后,P-170阴性患者完全缓解率[AML:86%(74/86);ALL:85%(24/28)]明显高于P-170阳性患者[AML:16%(2/12);ALL:0%(0/5)]。[结论]P-170可作为临床判断急性白血病疗效和预后的指标。更多还原

【Abstract】 [Objective] To investigate the expression of P-170 in acute leukemia patients and its relationship with the prognosis of this disease.[Methods] One hundred ninety-one acute leukemia patients were divided into primordial group(n=127,94 AML patients and 33 ALL patients) and recurrent group(n=64,45 AML patients and 19 ALL patients).The expression of P-170 in bone marrow cells was detected by flow cytometry,and was compared between primordial and recurrent groups.In addition,all the primordial patients received a formal chemotherapy.Complete remission(CR) was compared between P-170 positive and negative patients.[Results] In the primordial group,the expression of P-170 was 18.34±12.19% in AML patients and 16.25±11.47% in ALL patients,while the percentage of P-170 positive patient was 12.7%(12/94) in AML patients and 15.1%(5 /33) in ALL patients respectively.Compared to primordial group,the expression of P170 significantly increased in recurrent group [AML:(35.29±16.82) % vs 68.8%(31/45),P<0.01;ALL:(38.24±12.17)% vs 68.4%(13/19),P<0.01].After chemotherapy,the CR percentage of P-170 negative patients [AML:86%(74/86);ALL:85%(24/28)] was significantly higher than that of P-170 positive patients [AML:16%(2/12);ALL:0%(0/5)](P<0.01).[Conclusion] P-170 might be a promising marker in evaluating the therapeutic efficacy and prognosis of acute leukemia.更多还原